Low
₹
High
₹
| Previous Close | ₹41.40 |
|---|---|
| Day's Range | ₹41.20 - ₹41.80 |
| Open | ₹41.80 |
| 52 Week Range | ₹30.00 - ₹58.28 |
| Volume | 2,352 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 0.97 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 2.41 |
| Price/Earning (TTM) | 25.80 |
| TTM EPS (₹) | 1.61 |
| P/E Ratio | 30.50 |
| Book Value(₹) | 1.20 |
| PAT Margin (%) | 2.31 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 6.92 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 671.92 | 140.69 |
| Expenses | N/A | N/A |
| PBT | 21.56 | 3.42 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 15.49 | 3.26 |
| Founded | 1985 |
|---|
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,792.16 | 1,861.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,151.98 | 6,705.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,52,914.73 | 4,524.00 | 3,165.00 - 3,165.00 |
| Apollo Hospitals Enterprise Ltd. | 1,23,557.75 | 8,589.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,353.96 | 1,439.95 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,12,681.23 | 1,351.00 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,09,875.05 | 1,100.70 | 835.50 - 835.50 |
| Max Healthcare Institute Ltd. | 1,09,280.68 | 1,122.85 | 903.00 - 903.00 |
| Lupin Ltd. | 1,07,090.72 | 2,346.00 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,01,632.12 | 2,462.80 | 1,909.70 - 1,909.70 |
No Records Found
Pursuant to the ‘Code of Conduct for Prevention of Insider Trading’ of the Company, SEBI (Prohibition of Insider Trading)Regulations, 2015 and clarification given by BSE vide its letter ref no LIST/COMP/01/2019-20 dated April 2,2019 regarding trading restrictions period, Sandu Pharmaceuticals has informed that the trading window for dealing in Securities of the Company shall remain closed from Wednesday, 01 July 2026 till 48 hours after the declaration of the financial results of the Company for the quarter ended 30th June 2026 for Directors, KMPs, Promoters And Promoters Group and Designated Persons ,Immediate Relative etc covered under the Code. The date of the Board Meeting for consideration of the Un Audited Financial Results of the Company for the Quarter ended 30th June 2026 will be intimated in due course. Accordingly, all Designated Persons and their immediate relatives are advised not to trade in the securities of the Company during the aforesaid trading window closure period.
No Records Found
The current share price of Sandu Pharmaceuticals Ltd. is ₹41.40 as of 2026-06-25.
The market capitalisation of Sandu Pharmaceuticals Ltd. is ₹40.04 as of 2026-06-25.
The 1-year return of Sandu Pharmaceuticals Ltd. is -9.14% as of 2025-06-24.
The P/E ratio of Sandu Pharmaceuticals Ltd. is 30.50 as of 2026-06-25.
The 52-week high and low of Sandu Pharmaceuticals Ltd. are ₹58.28 and ₹30.00, respectively, as of 2026-06-25.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.